This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Cardiac 123I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan
- Introduction to Cardiac Neuronal Imaging: A Clinical Perspective
- Neuronal Dysfunction and Medical Therapy in Heart Failure: Can an Imaging Biomarker Help to "Personalize" Therapy?
- A Pooled Analysis of Multicenter Cohort Studies of 123I-mIBG Imaging of Sympathetic Innervation for Assessment of Long-Term Prognosis in Heart Failure
- Evaluation of LMI1195, a Novel 18F-Labeled Cardiac Neuronal PET Imaging Agent, in Cells and Animal Models
- Myocardial Iodine-123 Meta-Iodobenzylguanidine Imaging and Cardiac Events in Heart Failure: Results of the Prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) Study
- Cardiac Sympathetic Imaging With mIBG in Heart Failure
- Predicting the Need for an Implantable Cardioverter Defibrillator Using Cardiac Metaiodobenzylguanidine Activity Together with Plasma Natriuretic Peptide Concentration or Left Ventricular Function
- Effects of Carvedilol on Myocardial Sympathetic Innervation in Patients with Chronic Heart Failure
- Improvement of Cardiac Sympathetic Innervation by Renal Transplantation
- Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: A prospective study
- Myocardial Adrenergic Dysinnervation in Dilated Cardiomyopathy: Cornerstone or Epiphenomenon?